



Dedicated To Life

June 16, 2026

**BSE Limited**

1<sup>st</sup> Floor, P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

Re.: Completion of merger of Assertio Holdings Inc. (“Assertio”)

Ref.: Our Press Release dated June 16, 2026

Dear Sir / Madam,

Further to the Press Release dated June 16, 2026, Zydus Lifesciences Limited (“the **Company**”) hereby inform that Zara Merger Sub Inc., a step down wholly owned acquisition subsidiary (“**Zara**”) of the Company is merged with and into Assertio, pursuant to which Assertio has become a wholly owned subsidiary of the Company. The common stocks of Assertio are no longer listed or traded on the Nasdaq Global Market.

Accordingly, the acquisition of all the outstanding shares of common stock of Assertio through a merger process is completed.

In view of the above, the transaction of acquisition of shares of Assertio and merger of Zara into Assertio has been consummated today.

The disclosure as required under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, read with SEBI Master Circular is provided at **Annexure-“1”**.

Thanking you,  
Yours faithfully,

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Encl.:** As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878





Dedicated To Life

Annexure-“1”

Sr. No.	Particulars	Response
1.	name of the entity(ies) forming part of the amalgamation/merger, details in brief such as, size, turnover etc	<p>Zara Merger Sub Inc., a step down wholly owned subsidiary of the Company (“Zara”) got merged into Assertio Holdings Inc. (“Assertio”), a Nasdaq listed (Nasdaq: ASRT) pharmaceutical company having its registered office in Delaware, USA.</p> <p>Zara was incorporated on April 24, 2026 as an acquisition subsidiary.</p> <p>The adjusted turnover of Assertio for ROLVEDON® (surviving product, post asset sale of products on April 8, 2026, to Cosette Pharmaceuticals Inc.) for the calendar year ended on December 31, 2025, was USD 68.23 million.</p>
2.	whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	No.
3.	area of business of the entity(ies);	<p>Zara was incorporated as an acquisition subsidiary.</p> <p>Assertio is a U.S. based specialty oncology pharmaceutical company with established commercial capability of marketing and distribution of differentiated oncology products.</p> <p>Assertio’s product ROLVEDON® (eflapegrastim-xnst) is approved as Biologics License Application (BLA) by USFDA for long acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy.</p> <p>ROLVEDON® is administered once per chemotherapy cycle in the oncology supportive care market. Assertio is headquartered in Lake Forest, Illinois.</p>





Dedicated To Life

Sr. No.	Particulars	Response
4.	rationale for amalgamation / merger;	The merger was to acquire outstanding shares and control over Assertio as a wholly owned subsidiary of the Company.
5.	in case of cash consideration-amount or otherwise share exchange ratio;	Offer price of USD 23.50 per share in cash, representing total consideration of USD 166.33 million on a fully diluted basis, including payment of consideration deposited with the paying agent, for common stock not tendered into the offer having the right to receive cash equal to the offer price.
6.	brief details of change in shareholding pattern (if any) of listed entity.	Not applicable

For, **Zydus Lifesciences Limited**

**Dhaval N. Soni**  
**Company Secretary and Compliance Officer**  
**Membership No. FCS7063**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

